NCT04511637 - Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on the Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 15 mg in Japanese Healthy Male Adult Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 21, 2019

Primary Completion Date

March 7, 2019

Study Completion Date

April 12, 2019

Conditions

Clinical Pharmacology

Interventions

DRUG

Rivaroxaban (BAY 59-7939, Xarelto) in ODT form

15 mg as 1 x 15 mg orally disintegrating tablet (ODT)

DRUG

Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form

15 mg as 1 x 15 mg film-coated tablet

Trial Locations (3)

Sumida Hospital, Sumida-ku

Fukuoka Mirai Hospital, Fukuoka

Medical Co. LTA Nishikumamoto hospital, Kumamoto